Status:

UNKNOWN

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Lead Sponsor:

Luke Nordquist, MD

Collaborating Sponsors:

Clarity Pharmaceuticals

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.

Detailed Description

This is a prospective, non-randomized, single arm, single center, open-label study of 64Cu-SAR-bisPSMA PET in patients with known or suspected prostate cancer (PC). Patients will be screened during a...

Eligibility Criteria

Inclusion

  • Signed an informed consent.
  • \>18 years of age.
  • Known diagnosis of prostate adenocarcinoma confirmed by histopathology OR patients with suspicion of prostate cancer based on elevated PSA but negative standard of care imaging and/or negative biopsy.
  • The Eastern Cooperative Oncology (ECOG) performance status 0-2.
  • Adequate recovery from acute toxic effects of any prior therapy.
  • Adequate renal function (eGFR of 30 ml/min/1.73m2 or higher)

Exclusion

  • Participants must not receive other investigational agents within 28 days prior to 64Cu-SAR-bisPSMA administration.
  • Patients administered any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to 64Cu-SAR-bisPSMA administration.
  • Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
  • Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Key Trial Info

Start Date :

March 28 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2023

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT05286840

Start Date

March 28 2022

End Date

September 30 2023

Last Update

March 18 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

GU Research Network

Omaha, Nebraska, United States, 68130